Evidence map›Paper›PMID 42115428›Full record

ArticleLab animal2026

Alternative antibiotic regimens improve palatability and welfare in mice for gut bacterial depletion.

Kaoutar Abaakil, Yang Bi, Laetitia Firmenich, Xuan Yang, Mariam Alireza, Shahriar Mueed, Monica Campos, Marko Storch, Despoina Chrysostomou, Julian R Marchesi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lab animal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kaoutar Abaakil *Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.ORCID http://orcid.org/0009-0008-9614-0599
Yang Bi *Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.
Laetitia FirmenichDivision of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.
Xuan YangDivision of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.
Mariam AlirezaDivision of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.
Shahriar MueedDivision of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.
Monica CamposLondon Biofoundry, Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK.
Marko StorchLondon Biofoundry, Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK.
Despoina ChrysostomouDivision of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.
Julian R MarchesiDivision of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.
Jia V LiDivision of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK. jia.li@imperial.ac.uk.ORCID http://orcid.org/0000-0002-5763-6670

Funding

EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 715662
6 · The paper itself

Abstract

Here we evaluated vancomycin-neomycin or enrofloxacin-ampicillin treatments as alternatives to the poorly tolerated ampicillin-metronidazole-vancomycin-neomycin cocktail for gut bacterial depletion in mice. Both regimens were well tolerated in drinking water and did not reduce food intake or body weight. Metabolic profiling showed reduced bacterial metabolic activity in both groups, but a marked reduction in total bacterial abundance only in the enrofloxacin-ampicillin group. These findings support enrofloxacin-ampicillin as a refined antibiotic strategy for gut bacterial depletion, improving palatability and welfare.

Indexed as

Animal WelfareAnti-Bacterial AgentsAmpicillinAnimalsEnrofloxacinFemaleFluoroquinolonesMaleMetronidazoleMiceNeomycinVancomycinAmpicillinAnti-Bacterial AgentsEnrofloxacinFluoroquinolonesMetronidazoleNeomycinVancomycin

Identifiers

PMID42115428
PMCPMC13318628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.